![]() |
|
|
Department of Nutrition, The Pennsylvania State University, 126 South Henderson, University Park, PA 16802
2To whom correspondence should be addressed. E-mail: mxc69{at}psu.edu.
Determinations of the effects of iron status on the immune system are complicated by the fact that microorganisms and immune cells both utilize iron. To determine the role of iron in immune function, we utilized a model [experimental autoimmune encephalomyelitis (EAE)] in which a strong antigen-specific CD4+ T-cell response develops in the absence of infection. EAE is an autoimmune disease frequently used as a model for the human disease multiple sclerosis (MS). EAE was induced in B10.PL mice fed low iron (1 mg/kg), normal iron (10 mg/kg) or high iron (160 mg/kg) diets that were replete in all other nutrients. Liver iron measurements verified iron status, i.e., low iron mice had 1.9 µmol/g tissue, normal iron mice, 3.27 µmol/g tissue and high iron mice, 5.35 µmol/g tissue. EAE symptoms were most severe in normal iron mice, and EAE did not develop in low iron mice. The incidence of EAE was 71% in normal iron mice, 62% in iron-overloaded mice and 0% in iron-deficient mice. Two of seven mice in the normal iron group developed severe EAE and were euthanized. None of the iron-overloaded mice developed severe EAE. Other measures of EAE severity were similar in the normal and iron-overloaded mice. The data suggest that iron deficiency provides protection from the development of EAE and that iron excess with its potential contribution to free radical formation was not an important factor. The mechanism of EAE inhibition in iron-deficient mice likely involves the delivery and metabolism of iron for optimal CD4+ T-cell development.
KEY WORDS: iron experimental autoimmune encephalomyelitis multiple sclerosis mice
This article has been cited by other articles:
![]() |
K.M. Mitchell, A.L. Dotson, K.M. Cool, A. Chakrabarty, S.H. Benedict, and S.M. LeVine Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis Multiple Sclerosis, November 1, 2007; 13(9): 1118 - 1126. [Abstract] [PDF] |
||||
![]() |
Y. Ge, J.H. Jensen, H. Lu, J.A. Helpern, L. Miles, M. Inglese, J.S. Babb, J. Herbert, and R.I. Grossman Quantitative Assessment of Iron Accumulation in the Deep Gray Matter of Multiple Sclerosis by Magnetic Field Correlation Imaging AJNR Am. J. Neuroradiol., October 1, 2007; 28(9): 1639 - 1644. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ehrenreich, B. Fischer, C. Norra, F. Schellenberger, N. Stender, M. Stiefel, A.-L. Siren, W. Paulus, K.-A. Nave, R. Gold, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis Brain, October 1, 2007; 130(10): 2577 - 2588. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Zamboni The Big Idea: Iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis J R Soc Med, November 1, 2006; 99(11): 589 - 593. [Full Text] [PDF] |
||||
![]() |
C. Sfagos, A. C Makis, A. Chaidos, E. C Hatzimichael, A. Dalamaga, K. Kosma, and K. L. Bourantas Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients Multiple Sclerosis, June 1, 2005; 11(3): 272 - 275. [Abstract] [PDF] |
||||
![]() |
S. Leung, A. Holbrook, B. King, H.-T. Lu, V. Evans, N. Miyamoto, C. Mallari, S. Harvey, D. Davey, E. Ho, et al. Differential Inhibition of Inducible T Cell Cytokine Secretion by Potent Iron Chelators J Biomol Screen, March 1, 2005; 10(2): 157 - 167. [Abstract] [PDF] |
||||